The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

Diabetes Obes Metab. 2007 Jan;9(1):132-3. doi: 10.1111/j.1463-1326.2006.00582.x.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Body Weight / drug effects
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Metabolic Syndrome / drug therapy*
  • Middle Aged
  • Pioglitazone
  • Thiazolidinediones / therapeutic use*

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Pioglitazone